Carine Maenhaut
Overview
Explore the profile of Carine Maenhaut including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
42
Citations
843
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Van Branteghem C, Henry N, Craciun L, Maenhaut C
Int J Mol Sci
. 2025 Feb;
26(4).
PMID: 40004107
Thyroid cancer is the most prevalent endocrine malignancy, and papillary thyroid carcinoma (PTC) is the most common type of thyroid malignancy. While PTC generally has a favorable prognosis, a subset...
2.
Quiriny M, Rodrigues Vitoria J, Saiselet M, Dom G, de Saint Aubain N, Willemse E, et al.
Cancers (Basel)
. 2025 Jan;
16(24.
PMID: 39766113
Background: The diagnosis of malignant thyroid nodules is mainly based on the fine-needle aspiration biopsy (FNAB). To improve the detection of malignant nodules, different molecular tests have been developed. We...
3.
Rojo-Pardillo M, Godefroid L, Dom G, Lefort A, Libert F, Robaye B, et al.
Int J Mol Sci
. 2024 Oct;
25(19).
PMID: 39409030
Tumors originating from thyroid follicular cells are the most common endocrine tumors, with rising incidence. Despite a generally good prognosis, up to 20% of patients experience recurrence and persistence, highlighting...
4.
Pita J, Raspe E, Coulonval K, Decaussin-Petrucci M, Tarabichi M, Dom G, et al.
Front Endocrinol (Lausanne)
. 2023 Nov;
14:1247542.
PMID: 37964967
Background: CDK4/6 inhibitors (CDK4/6i) have been established as standard treatment against advanced Estrogen Receptor-positive breast cancers. These drugs are being tested against several cancers, including in combinations with other therapies....
5.
Van Branteghem C, Augenlicht A, Demetter P, Craciun L, Maenhaut C
Int J Mol Sci
. 2023 Jul;
24(13).
PMID: 37445942
Thyroid cancer is the most common endocrine malignant tumor with an increasing incidence rate. Although differentiated types of thyroid cancer generally present good clinical outcomes, some dedifferentiate into aggressive and...
6.
Jacquemin V, Antoine M, Dom G, Detours V, Maenhaut C, Dumont J
Cancers (Basel)
. 2022 Jan;
14(2).
PMID: 35053446
Though heterogeneity of cancers is recognized and has been much discussed in recent years, the concept often remains overlooked in different routine examinations. Indeed, in clinical or biological articles, reviews,...
7.
Tarabichi M, Demetter P, Craciun L, Maenhaut C, Detours V
Mol Cell Endocrinol
. 2021 Nov;
541:111491.
PMID: 34740746
The vast majority of thyroid cancers originate from follicular cells. We outline outstanding issues at each step along the path of cancer patient care, from prevention to post-treatment follow-up and...
8.
Augenlicht A, Saiselet M, Decaussin-Petrucci M, Andry G, Dumont J, Maenhaut C
Oncotarget
. 2021 Aug;
12(16):1587-1599.
PMID: 34381564
The aberrant expression of miRNAs is often correlated to tumor development. MiR-7-5p is a recently discovered downregulated miRNA in thyroid papillary carcinoma (PTC). The goal of this project was to...
9.
Dom G, Dmitriev P, Lambot M, Van Vliet G, Glinoer D, Libert F, et al.
Front Cell Dev Biol
. 2021 Jul;
9:669354.
PMID: 34249923
The human thyroid gland acquires a differentiation program as early as weeks 3-4 of embryonic development. The onset of functional differentiation, which manifests by the appearance of colloid in thyroid...
10.
Saiselet M, Rodrigues-Vitoria J, Tourneur A, Craciun L, Spinette A, Larsimont D, et al.
J Mol Cell Biol
. 2020 Jun;
12(11):906-908.
PMID: 32573704
No abstract available.